跳轉至內容
Merck

MicroRNAs in endometrial cancers from black and white patients.

American journal of obstetrics and gynecology (2014-09-02)
G Larry Maxwell, Yutaka Shoji, Kathleen Darcy, Tracy Litzi, Andrew Berchuck, Chad A Hamilton, Thomas P Conrads, John I Risinger
摘要

Previous studies have identified differences in gene mutations among endometrial cancers from whites and blacks suggesting that differences in tumor biology may explain racial disparities in patient outcome. Micro RNAs (miRNAs) have emerged as regulators of transcript expression and their aberrant expression has been discovered in many diseases, including endometrial cancer. We performed quantitative polymerase chain reaction-based analysis in a set of endometrial cancers to identify whether there are racial differences in miRNA expression. Tumor cells from 50 stage-I endometrioid endometrial cancer specimens from 41 white and 9 black patients were prepared by laser microdissection and miRNA extracts were analyzed using TaqMan (Life Technologies, Carlsbad, CA) low-density arrays. Statistically significant, differentially expressed miRNAs between blacks and whites were identified using multidimensional scaling, Wilcoxon testing, and analysis of variance. There were no global differences in miRNA expression between endometrial cancers from 41 white and 9 black patients. To minimize potential bias introduced by unbalanced sample size, we performed a subset analysis with stage- and histology-matched specimens from 9 whites and 9 blacks that identified 18 differentially abundant miRNAs (>2-fold at P < .005). Quantitative polymerase chain reaction validated miRNA-337-3p in an independent set of endometrial cancer specimens from 23 white and 24 black women. There were no racial differences in hsa-miR-337-3p expression in normal endometrium. These data indicate that hsa-mir-337-3p is more frequently down-regulated in endometrial cancers from whites compared to blacks. Future studies are focused on determining the phenotypic impact of miR-337-3p and whether its differential expression is associated with clinical outcome.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
十二烷基硫酸钠, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC)
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠, ≥99.0% (GC), dust-free pellets
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠 溶液, BioUltra, for molecular biology, 10% in H2O
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠 溶液, BioUltra, for molecular biology, 20% in H2O
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠, BioUltra, for molecular biology, ≥99.0% (GC)
暫時無法取得訂價和供貨情況
Supelco
十二烷基硫酸钠, dust-free pellets, suitable for electrophoresis, for molecular biology, ≥99.0% (GC)
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠, ≥98.0% (GC)
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠, ACS reagent, ≥99.0%
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠, ReagentPlus®, ≥98.5% (GC)
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠, BioXtra, ≥99.0% (GC)
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠, 92.5-100.5% based on total alkyl sulfate content basis
暫時無法取得訂價和供貨情況
Supelco
十二烷基硫酸钠, suitable for ion pair chromatography, LiChropur, ≥99.0%
暫時無法取得訂價和供貨情況
Sigma-Aldrich
十二烷基硫酸钠, ≥90% ((Assay))
暫時無法取得訂價和供貨情況
月桂基硫酸钠, European Pharmacopoeia (EP) Reference Standard
暫時無法取得訂價和供貨情況